Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Inclusion Criteria: Must satisfy A and B and C below: A. Women aged 45+ B. Postmenopausal C. Osteoporotic with high risk of fracture Exclusion Criteria: * History of significant hepatic, renal, cardiovascular, malignant disease, or conditions with impaired immune system * Current alcohol or substance abuse * Major psychiatric disorders * Abnormal calcium level, elevated PTH, vitamin D deficiency, or anemia * Known congenital or acquired bone disease other than osteoporosis * Current use or past use in the past 12 months of oral bisphosphonates * Current use or use in the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin * Use of oral or parenteral glucocorticoids for more than 14 days in the past 6 months * Any current or previous use of strontium or intravenous bisphosphonates * Sensitivity to cell-derived drug products or teriparatide * Extensive dental work involving dental extraction or dental implant within the past 2 months or in the upcoming 2 months * Inability to sit upright for 30 minutes * Esophageal abnormalities